BioSpace News Archive

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the composition of COM701 or backup antibodies for the treatment of cancer. EPO Patent No. 3295951 , titled “Anti-P

Teladoc Health, Inc., the global leader in virtual care, announced that it will release first-quarter 2020 results on Wednesday, April 29th, 2020, after the market closes.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies and the utilization of novel biomarkers to enhance patient selection, today announced that the Company will host a conference call and webcast on April 30, 2020 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2020 financial results.

Vericel Corporation announced the following webcast and conference call to discuss its first-quarter 2020 financial results and business highlights.

Predictive Oncology announces that Company director and CEO Dr. Carl Schwartz, in an interview with NetworkNewsWire, discussed the Predictive Oncology’s distinctive business model and significant changes management is making to position the Company for the future.

New Laboratory Tests Conducted by Utah-Based Institute for Antiviral Research Confirm SaNOtize’s Nitric Oxide Releasing Solution (NORS TM ) is Over 99.9% Effective Against SARS-CoV-2, the Virus that Causes COVID-19 VANCOUVER , April 22, 2020 /CNW/ - SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) today announced that it has be

Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020 . A press release announcing the results is scheduled for release after the close of trading on that date. Management will hold a conference call to discuss the operating highlight

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal, prostate and leukemia, today announced the election of three new independent Directors to its Board of Directors; Dr. James Armitage , Ms. Lâl

Artificial Intelligence (AI) and computational biophysics will be deployed to rapidly develop drugs for COVID-19 and other viral infections based on Mannin Research’s Tie2 platform in new joint venture with Cyclica

HBI Solutions, a leader in predictive analytics for healthcare announces it has recently passed certification on a partial list of 2020 HEDIS® measures.